Nanoform Finland Oyj

OM:NANOFS Stock Report

Market Cap: SEK 1.2b

Nanoform Finland Oyj Valuation

Is NANOFS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NANOFS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NANOFS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NANOFS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NANOFS?

Key metric: As NANOFS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NANOFS. This is calculated by dividing NANOFS's market cap by their current revenue.
What is NANOFS's PS Ratio?
PS Ratio43.3x
Sales€2.43m
Market Cap€105.20m

Price to Sales Ratio vs Peers

How does NANOFS's PS Ratio compare to its peers?

The above table shows the PS ratio for NANOFS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.6x
GENO Genovis AB (publ.)
12.3x10.1%SEK 1.6b
MAGLE Magle Chemoswed Holding
3x27.0%SEK 625.7m
BICO BICO Group
1x10.9%SEK 2.3b
PRO Promimic
10xn/aSEK 447.8m
NANOFS Nanoform Finland Oyj
43.3x55.7%SEK 105.2m

Price-To-Sales vs Peers: NANOFS is expensive based on its Price-To-Sales Ratio (43.3x) compared to the peer average (6.6x).

Price to Sales Ratio vs Industry

How does NANOFS's PS Ratio compare vs other companies in the European Life Sciences Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
NANOFS 43.3xIndustry Avg. 4.3xNo. of Companies7PS03.26.49.612.816+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NANOFS is expensive based on its Price-To-Sales Ratio (43.3x) compared to the European Life Sciences industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is NANOFS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NANOFS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio43.3x
Fair PS Ratio13.1x

Price-To-Sales vs Fair Ratio: NANOFS is expensive based on its Price-To-Sales Ratio (43.3x) compared to the estimated Fair Price-To-Sales Ratio (13.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NANOFS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 14.10
SEK 40.50
+187.2%
14.3%SEK 46.29SEK 34.72n/a2
Dec ’25SEK 17.00
SEK 40.50
+138.2%
14.3%SEK 46.29SEK 34.72n/a2
Sep ’25SEK 21.35
SEK 48.13
+125.4%
5.9%SEK 50.96SEK 45.30n/a2
Aug ’25SEK 19.98
SEK 49.49
+147.7%
5.9%SEK 52.40SEK 46.58n/a2
Jul ’25SEK 19.10
SEK 49.49
+159.1%
5.9%SEK 52.40SEK 46.58n/a2
Jun ’25SEK 23.35
SEK 49.49
+111.9%
5.9%SEK 52.40SEK 46.58n/a2
May ’25SEK 25.60
SEK 49.53
+93.5%
2.3%SEK 50.66SEK 48.40n/a2
Apr ’25SEK 31.80
SEK 49.53
+55.8%
2.3%SEK 50.66SEK 48.40n/a2
Mar ’25SEK 34.30
SEK 49.19
+43.4%
2.3%SEK 50.31SEK 48.07n/a2
Feb ’25SEK 33.90
SEK 50.36
+48.6%
2.3%SEK 51.51SEK 49.22n/a2
Jan ’25SEK 18.80
SEK 50.36
+167.9%
2.3%SEK 51.51SEK 49.22n/a2
Dec ’24SEK 19.20
SEK 50.36
+162.3%
2.3%SEK 51.51SEK 49.22SEK 17.002
Nov ’24SEK 18.85
SEK 71.60
+279.9%
8.3%SEK 77.57SEK 65.64SEK 15.242
Oct ’24SEK 21.70
SEK 71.60
+230.0%
8.3%SEK 77.57SEK 65.64SEK 17.882
Sep ’24SEK 29.30
SEK 71.60
+144.4%
8.3%SEK 77.57SEK 65.64SEK 21.352
Aug ’24SEK 21.70
SEK 81.20
+274.2%
21.4%SEK 98.60SEK 63.80SEK 19.982
Jul ’24SEK 23.90
SEK 81.20
+239.8%
21.4%SEK 98.60SEK 63.80SEK 19.102
Jun ’24SEK 25.70
SEK 81.20
+216.0%
21.4%SEK 98.60SEK 63.80SEK 23.352
May ’24SEK 25.70
SEK 79.57
+209.6%
23.1%SEK 97.93SEK 61.21SEK 25.602
Apr ’24SEK 18.02
SEK 79.57
+341.6%
23.1%SEK 97.93SEK 61.21SEK 31.802
Mar ’24SEK 24.30
SEK 79.57
+227.4%
23.1%SEK 97.93SEK 61.21SEK 34.302
Feb ’24SEK 34.50
SEK 93.74
+171.7%
12.7%SEK 105.62SEK 81.85SEK 33.902
Jan ’24SEK 37.00
SEK 93.74
+153.3%
12.7%SEK 105.62SEK 81.85SEK 18.802
Dec ’23SEK 35.65
SEK 93.74
+162.9%
12.7%SEK 105.62SEK 81.85SEK 19.202

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 06:27
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nanoform Finland Oyj is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lars HevrengDanske Bank
Sami SarkamiesDanske Bank
Christian GlennieStifel, Equities Research